Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Thorac Oncol. 2020 Dec 8;16(3):419–427. doi: 10.1016/j.jtho.2020.11.021

Fig. 3. Non-prognostic nature of the compound mutation signature in non-ICB treated NSCLC patients from the MSK-IMPACT cohort.

Fig. 3.

Kaplan-Meier analysis of the OS levels in a sub-cohort of 1193 non-ICB treated NSCLC patients from the MSK-IMACT cohort with different mutation signatures. HR (compound vs wt): 1.7 (95% [CI]: 1.32–2.20). P values calculated by use of logrank test.